ATE315231T1 - Verfahren zur feststellung der anwesenheit mutierten brca proteins - Google Patents

Verfahren zur feststellung der anwesenheit mutierten brca proteins

Info

Publication number
ATE315231T1
ATE315231T1 AT98910509T AT98910509T ATE315231T1 AT E315231 T1 ATE315231 T1 AT E315231T1 AT 98910509 T AT98910509 T AT 98910509T AT 98910509 T AT98910509 T AT 98910509T AT E315231 T1 ATE315231 T1 AT E315231T1
Authority
AT
Austria
Prior art keywords
determining
relates
protein
proteins
mutated brca
Prior art date
Application number
AT98910509T
Other languages
English (en)
Inventor
Lorrie A Adams
Timothy J Byrne
Gabriel M Cohn
Margaret T Reece
Original Assignee
Baystate Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baystate Medical Ct filed Critical Baystate Medical Ct
Application granted granted Critical
Publication of ATE315231T1 publication Critical patent/ATE315231T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT98910509T 1997-03-24 1998-03-23 Verfahren zur feststellung der anwesenheit mutierten brca proteins ATE315231T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4233797P 1997-03-24 1997-03-24

Publications (1)

Publication Number Publication Date
ATE315231T1 true ATE315231T1 (de) 2006-02-15

Family

ID=21921326

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98910509T ATE315231T1 (de) 1997-03-24 1998-03-23 Verfahren zur feststellung der anwesenheit mutierten brca proteins

Country Status (7)

Country Link
US (1) US5965377A (de)
EP (1) EP0975973B1 (de)
AT (1) ATE315231T1 (de)
AU (1) AU6473598A (de)
CA (1) CA2284817C (de)
DE (1) DE69833105D1 (de)
WO (1) WO1998043092A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
AU7701100A (en) * 1999-09-03 2001-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US20030188326A1 (en) * 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
KR100468466B1 (ko) * 2001-08-25 2005-01-27 주식회사 랩 지노믹스 유방암 및 난소암 진단에 유용한 ｂｒｃａ１, ｂｒｃａ２유전자 돌연변이 및 이를 이용한 검색 방법
US7955288B2 (en) 2002-12-11 2011-06-07 Ferrosan Medical Devices A/S Gelatine-based materials as swabs
US8642831B2 (en) 2008-02-29 2014-02-04 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
WO2012071096A2 (en) 2010-09-03 2012-05-31 The Johns Hopkins University Arid1a and ppp2r1a mutations in cancer
WO2013131520A2 (en) 2012-03-06 2013-09-12 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
AU2013265163B2 (en) 2012-05-25 2017-08-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Ulipristal acetate for prevention and treatment of breast tumors
CN104349797B (zh) 2012-06-12 2017-10-27 弗罗桑医疗设备公司 干止血组合物
WO2014202760A2 (en) 2013-06-21 2014-12-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
JP6726852B2 (ja) 2014-10-13 2020-07-22 フェッローサン メディカル ディバイス エー／エス 止血および創傷治癒に使用するための乾燥組成物
WO2016102446A1 (en) 2014-12-24 2016-06-30 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
WO2017005590A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
EP3631018B1 (de) * 2017-05-26 2024-07-24 Life Technologies Corporation Verfahren zur erkennung umfangreicher neuanordnungen bei brca1/2
WO2019079297A1 (en) 2017-10-16 2019-04-25 Dana-Farber Cancer Institute, Inc. COMPOUNDS AND METHODS OF TREATING CANCER
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283190A (en) * 1989-07-31 1994-02-01 Traish Adbulmaged M Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
US5252458A (en) * 1990-12-31 1993-10-12 Symex Corp. Method for visually detecting the presence of a virus in a clinical specimen
US5622829A (en) * 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
WO1996005308A1 (en) * 1994-08-12 1996-02-22 Myriad Genetics, Inc. Method for diagnosing a predisposition for breast and ovarian cancer
MX9701075A (es) * 1994-08-12 1998-03-31 Myriad Genetics Inc Mutaciones en vivo y polimorfismos en el gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
US5645995A (en) * 1996-04-12 1997-07-08 Baylor College Of Medicine Methods for diagnosing an increased risk for breast or ovarian cancer
US5905026A (en) * 1996-08-27 1999-05-18 Cornell Research Foundation, Inc. Method of detecting expression of and isolating the protein encoded by the BRCA1 gene

Also Published As

Publication number Publication date
EP0975973A1 (de) 2000-02-02
EP0975973B1 (de) 2006-01-04
AU6473598A (en) 1998-10-20
CA2284817A1 (en) 1998-10-01
CA2284817C (en) 2003-08-19
WO1998043092A1 (en) 1998-10-01
US5965377A (en) 1999-10-12
DE69833105D1 (de) 2006-03-30

Similar Documents

Publication Publication Date Title
ATE315231T1 (de) Verfahren zur feststellung der anwesenheit mutierten brca proteins
DE69519834D1 (de) Verfahren zum Nachweis von Prädisposition von Ovarial- und Brustkrebs
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
DE60041839D1 (de) Auto-Antikörper gegen Annexin-Proteine als Marker für Lungenkrebs
MXPA01009567A (es) Aislamiento y analisis de proteina.
DE59710933D1 (de) Messanordnung zur optischen Bestimmung der totalen Hämoglobinkonzentration
DE69521002D1 (de) Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
ATE322014T1 (de) Krebsnachweisverfahren und reagenzien
DE69903898D1 (de) Teststreifen zur visuellen Ermittlung der Blutglukose-Konzentration
NZ515311A (en) Mass screening and highly specific early identification of colorectal or metastatic breast cancer by measuring TIMP-1 tissue inhibitor
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
IL71699A0 (en) Methods and kits for the analysis and detection of biological or genetic material
AU7571998A (en) Rapid evaluation of the ratio of biological molecules
PT981644E (pt) Mutacao apc associada com o cancro colorectal familiar em judeus ashkenazi
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
WO2001004343A3 (en) A method for determining the prognosis of cancer patients by measuring levels of bag expression
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
DE69839846D1 (de) Bestimmung der vorhandenen mengen an cyclin-abhängr bei krebspatienten
ATE320602T1 (de) Verfahren und testsatz zur evaluierung der metastasierungstendenz von tumoren
GB0110036D0 (en) Methods
EP0950062A4 (de) Proteinmarker für ösophaguskrebs
IL143639A0 (en) Method for determining the activity of a substance using a functional test in vitro

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties